Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression

Area of Science:

• Metabolic bone diseases
• Hepatology
• Cholesterol metabolism

Background:

• Hepatic osteodystrophy (HOD) is a metabolic bone disease associated with chronic liver disease, characterized by significant bone loss.
• The liver-bone axis in HOD pathogenesis remains incompletely understood, particularly concerning molecular mechanisms.
• Altered lipid metabolism and its impact on bone health in liver disease require further investigation.

Purpose of the Study:

• To investigate the role of hepatic phosphatase PP2Acα and hepatokine lecithin-cholesterol acyltransferase (LCAT) in the pathogenesis of HOD.
• To elucidate the mechanisms by which LCAT influences bone metabolism and liver function in a mouse model of HOD.
• To explore the potential of targeting the liver-bone axis for therapeutic intervention in HOD.

Main Methods:

• Utilized a mouse model of hepatic osteodystrophy.
• Assessed hepatic expression of PP2Acα and LCAT.
• Investigated the impact of LCAT deficiency on bone loss and liver fibrosis.
• Analyzed cholesterol levels and their effect on osteoblast and osteoclast activity.
• Examined the role of LCAT in reverse cholesterol transport from bone to liver.

Main Results:

• Hepatic expression of PP2Acα was upregulated in HOD, leading to decreased LCAT expression.
• Loss of LCAT function significantly exacerbated bone loss in the HOD mouse model.
• Alterations in cholesterol levels were found to regulate osteoblast and osteoclast activities.
• LCAT administration improved liver function and reduced liver fibrosis by promoting cholesterol transport from bone to liver.

Conclusions:

• Defects in the liver-bone axis are a key feature of hepatic osteodystrophy.
• Hepatic PP2Acα-mediated downregulation of LCAT contributes to HOD pathogenesis.
• Targeting the liver-bone axis, particularly LCAT function, holds therapeutic potential for HOD.